DR. JEFFREY ROBERTS LEE, M.D.
Medical Practice at Freedom Way, Augusta, GA

6372439, Apr 16, 2002

Oct 1, 1998

09/164954

James R. Goldenring - Martinez GA 30907
P. Henry Schmidt - Augusta GA 30909
Jeffrey R. Lee - Martinez GA 30907

G01N 3353

435 71, 435 4, 435 72, 435 723

It has been determined that a specific metaplastie lineage that contains immunoreactivity for a trefoil polypeptide, spasmolytic peptide, is associated with and gives rise to the vast majority of human adenocarcinomas. The identification of this Spasmolytic Polypeptide Expressing Metaplasia (SPEM) is a major factor for grading of biopsies of the stomach to assess risk for gastric cancer. It also forms the basis of a method for serological screening for those at risk for gastric cancer. In a preferred embodiment, antibodies to spasmolytic peptide (hSP) are used in immunostaining of biopsies of gastric tissue obtained by endoscopy for grading biopsies Those patients having these cells, characterized by a morphology more typical of a type of cell present normally in the intestine and not stomach, Brunners gland cells, are at risk of developing adenocarinoma. Since these cells express hSP, antibodies or nucleic acid probes hybridizing to mRNA encoding hSP, can be used for rapid detection of the cells in tissue biopsies. The antibodies can also be used in serological tests for screening and following patients at risk for gastric cancer.

6107048, Aug 22, 2000

Nov 20, 1997

8/974692

James R. Goldenring - Martinez GA
Gregory S. Ray - Snellville GA
Jeffrey R. Lee - Martinez GA

Medical College of Georgia Research Institute, Inc. - Augusta GA

G01N 3353, C07K 1600, C12Q 168

435 71

A method of detecting dysplastic regions within epithelial tissue samples is sensitive enough to detect and distinguish between low grade and high grade dysplastic regions. The method uses probes specific for expression and accumulation of substances within a particular intracellular region from a defect in apical membrane trafficking (trafficking markers) and in the preferred embodiment correlates the trafficking marker levels with the presence of an oncogene such as p53. If low grade dysplasia is present, trafficking markers are detected in a distinctive perinuclear pattern. Previous studies have demonstrated a high correlation of p53 over-expression with high grade dysplasia and adenocarcinoma. Detection of p53 is shown to be mutually exclusive of detection of trafficking markers. Therefore, dual detection for both the trafficking markers and p53 provides an accurate method for more precise grading of biopsies.

2010031, Dec 16, 2010

Jan 16, 2009

12/745404

William Dynan - Martinez GA, US
Hilal Arnouk - Birmingham AL, US
Mark Merkley - Augusta GA, US
Jeffrey Lee - Martinez GA, US
Daron Ferris - Evans GA, US
Hubert Stoppler - Foster City CA, US
Robert H. Podolsky - Martinez GA, US

C12Q 1/70, C12Q 1/02, C12Q 1/26

435 5, 435 29, 435 25

Biomarkers that correlate with progression to neoplasia in human papillomavirus (HPV) induced cancer, for example cervical cancer have been identified. These biomarkers can be used to diagnosis or assist in the diagnosis of HPV-induced cancer. They can also be used to increase the positive predictive value of current screening modalities. In addition, they can provide insights into the biology of HPV-induced cancer and thus provide leads for the development of nonsurgical therapies. Exemplary biomarkers include cornulin, PA28 β, DJ-1, actin, transthyretin, HSPB1, CV intracellular channel 1, cytokeratin 8, transferrin, Hsρβ6 (HSP20), aflatoxin reductase, α2 type I collagen, creatine kinase B, cytokeratin 13 GST π, PA28 α, Manganese SOD, lamin A/C, serpin B1 (elastase inhibitor), serpin B3 (SCAA1), cytokeratin 10, cytokeratin 6A, and trp-tRNA synthetase. Preferred biomarkers for HPV-induced cancer include cornulin, DJ-1, PA28 α, and PA28 β, trp-tRNA synthetase, HSPβ6, creatine kinase B, aflatoxin reductase, GST π, transthyretin, transferrin, α2-type 1 collagen, and combinations thereof.

2010026, Oct 21, 2010

Apr 1, 2010

12/798307

Andrew L. Mellor - Augusta GA, US
David H. Munn - Augusta GA, US
Jeffrey Roberts Lee - Martinez GA, US

C12Q 1/68, C12Q 1/26, G01N 33/53

435 6, 435 25, 435 71, 435 792

The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

2013032, Dec 5, 2013

Mar 15, 2013

13/840377

ANDREW L. MELLOR - AUGUSTA GA, US
JEFFREY ROBERTS LEE - MARTINEZ GA, US

GEORGIA HEALTH SCIENCES UNIVERSITY - AUGUST GA

C12N 5/0784

435325

The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

2012014, Jun 7, 2012

Feb 15, 2012

13/397152

ANDREW L. MELLOR - AUGUSTA GA, US
DAVID H. MUNN - AUGUSTA GA, US
JEFFREY ROBERTS LEE - MARTINEZ GA, US

GEORGIA HEALTH SCIENCES UNIVERSITY - AUGUSTA GA

C12Q 1/68, C12Q 1/26, G01N 33/574

435 611, 435 723, 435 25

The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

7763251, Jul 27, 2010

Jun 23, 2006

11/474144

Andrew L. Mellor - Augusta GA, US
David H. Munn - Augusta GA, US
Jeffrey Roberts Lee - Martinez GA, US

Medical College of Georgia Research Institute, Inc. - Augusta GA

A61K 39/395, C07K 16/00

4241531, 5303896

The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. Also disclosed are kits for assessing the relative risk of tumor progression in a subject. For example, disclosed are kits for assessing the relative risk of tumor progression in a subject and having reagents for detection of the enzyme indoleamine 2,3-dioxygenase (IDO) in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein the reagents are packaged in at least one individual container. The kits may include reagents for detection of cell surface or immunohistochemical markers associated with high IDO expression by APCs such as DO, CD123, CD11c or CCR6.